The decline in Allogene Therapeutics' stock price is directly related to the market's reaction to its future strategy announcement, which may have underwhelmed investors. The downgrades by JMP Securities and Guggenheim further exacerbate the negative sentiment, as analyst ratings can significantly influence investor perception and stock performance in the short term.